Teclistamab in Previously Treated Multiple Myeloma (MajesTEC-9) @NEJMgroup
Teclistamab in Previously Treated Multiple Myeloma (MajesTEC-9) @NEJMgroup
Uploaded August 2026 | Updated September 2026, 1 week ago
In relapsed multiple myeloma, teclistamab improved 18-month progression-free survival as compared with standard therapy. Grade 3 or 4 infections were common; antimicrobial prophylaxis and immune globulin support were recommended.

Read the full phase 3 MajesTEC-9 trial results and Research Summary at NEJM.org.

#hematology #clinicaltrials #nejm
Teclistamab in Previously Treated Multiple Myeloma (MajesTEC-9)NEJM Interview: Jean Nachega on the importance of investment in equitable partnerships, community...Ask the Expert: What’s the H2FPEF Score?Logistic Regression | NEJM EvidenceImage Challenge — July 23, 2026Original Article: Atezolizumab plus FOLFOX for Stage III Colon Cancer (ATOMIC)Dr. Glaucomflecken Explains: Clesrovimab for Prevention of RSV Disease in Healthy Infants (CLEVER)Images in Clinical Medicine: Bronchial Casts from Inhalation of Forest-Fire SmokeClinical Decisions: Operative versus Nonoperative Management for AppendicitisReview Article: GLP-1 Receptor AgonistsNEJM Interview: Raja-Elie Abdulnour on the need for clinicians and AI systems to refrain from exp...Clinical Decisions: Fast Track in Internal Medicine Residency
NEJM Group |

Teclistamab in Previously Treated Multiple Myeloma (MajesTEC-9)

SHARE TO X SHARE TO REDDIT SHARE TO FACEBOOK WALLPAPER